SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation

Recent data suggest that SRC family kinases (SFKs) could represent potential therapeutic targets for rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children. Here, we assessed the effect of a recently developed selective SFK inhibitor (a pyrazolo[3,4-d]pyrimidine derivative, called S...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Casini, Nadia, Forte, Iris Maria, Mastrogiovanni, Gianmarco, Pentimalli, Francesca, Angelucci, Adriano, Festuccia, Claudio, Tomei, Valentina, Ceccherini, Elisa, Di Marzo, Domenico, Schenone, Silvia, Botta, Maurizio, Giordano, Antonio, Indovina, Paola
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4494948/
https://ncbi.nlm.nih.gov/pubmed/25762618
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars